Cor Vasa 2018, 60(2):e144-e147 | DOI: 10.1016/j.crvasa.2017.12.006

Cardiorenal interactions

Vladimír Tesař*, Jan Vachek
Klinika nefrologie, 1. lékařská fakulta Univerzity Karlovy a Všeobecná fakultní nemocnice v Praze, Praha, Česká republika

Cardiorenal interactions are bidirectional. Renal hypoperfusion in patients with acute or chronic heart disease is associated with increased mortality and increased risk of end-stage renal disease. Heart damage and/or dysfunction in patients with acute and chronic kidney disease have significant negative impact on the patient survival. Awareness and early diagnosis and therapy may help to ameliorate negative consequences of the other organ damage, especially in acute setting. Search for therapeutic interventions aimed at concomitant cardio- and renoprotection is warranted.

Keywords: Cardiorenal syndrome; Chronic heart failure; Diabetic kidney disease; Empagliflozin; Renin-angiotensin system

Received: September 30, 2017; Revised: October 30, 2017; Accepted: November 5, 2017; Published: April 1, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Tesař V, Vachek J. Cardiorenal interactions. Cor Vasa. 2018;60(2):e144-147. doi: 10.1016/j.crvasa.2017.12.006.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. C. Ronco, P. McCullough, S.D. Anker, et al., Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative, European Heart Journal 31 (2010) 703-711. Go to original source... Go to PubMed...
    2. C. Quintavalle, C.V. Anselmi, F. De Micco, et al., Neutrophil gelatinase-associated lipocalin and contrast-induced acute kidney injury, Circulation: Cardiovascular Interventions 8 (2015) e002673, http://dx.doi.org/10.1161/CIRCINTERVENTIONS.115.002673. Go to original source... Go to PubMed...
    3. C. Chen, X. Yang, Y. Lei, et al., Urinary biomarkers at the time of AKI diagnosis as predictors of progression of AKI among patients with acute cardiorenal syndrome, Clinical Journal of the American Society of Nephrology 11 (2016) 1536-1544. Go to original source... Go to PubMed...
    4. G. Ramesh, C.D. Krawczeski, J.G. Woo, et al., Urinary netrin-1 is an early predictive biomarker of acute kidney injury after cardiac surgery, Clinical Journal of the American Society of Nephrology 5 (2010) 395-403. Go to original source... Go to PubMed...
    5. S.G. Coca, S. Singanamala, C.R. Parikh, Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis, Kidney International 81 (2012) 442-448. Go to original source... Go to PubMed...
    6. M.T. James, W.A. Ghali, M.L. Knudtson, et al., Associations between acute kidney injury and cardiovascular and renal outcomes after coronary angiography, Circulation 123 (2011) 409-416. Go to original source... Go to PubMed...
    7. A.P. Amin, J.A. Spertus, K.J. Reid, et al., The prognostic importance of worsening renal function during an acute myocardial infarction on long-term mortality, American Heart Journal 160 (2010) 1065-1071. Go to original source... Go to PubMed...
    8. A.M. Van Berendoncks, M.M. Elseviers, R.L. Lins, et al., Outcome of acute kidney injury with different treatment options: long-term follow-up, Clinical Journal of the American Society of Nephrology 5 (2010) 1755-1762. Go to original source... Go to PubMed...
    9. W. Vandeberghe, S. Gevaert, J.A. Kelum, et al., Acute kidney injury in cardiorenal syndrome type 1 patients: a systematic review and meta-analysis, Cardiorenal Medicine 6 (2016) 116-128. Go to original source... Go to PubMed...
    10. W. Ling, N. Zhaohui, H. Ben, et al., Urinary IL-18 and NGAL as early predictive biomarkers in contrast-induced nephropathy after coronary angiography, Nephron Clinical Practice 108 (2008) c176-c181. Go to original source... Go to PubMed...
    11. Y. Obi, T. Kim, C.P. Kovesdy, et al., Current and Potential Therapeutic Strategies for Hemodynamic Cardiorenal Syndrome, Cardiorenal Medicine 6 (2016) 83-98. Go to original source... Go to PubMed...
    12. M. Briet, P. Boutouyrie, S. Laurent, et al., Arterial stiffness and pulse pressure in CKD and ESRD, Kidney International 82 (2012) 388-400. Go to original source... Go to PubMed...
    13. D. Goldsmith, E. Ritz, A. Covic, Vascular calcification: a stiff challenge for the nephrologist: does preventing bone disease cause arterial disease?, Kidney International 66 (2004) 1315-1333. Go to original source... Go to PubMed...
    14. R. Haynes, N. Staplin, J. Emberson, et al., Evaluating the contribution of the cause of kidney disease to prognosis in CKD: results from the Study of Heart and Renal Protection (SHARP), American Journal of Kidney Diseases 64 (2014) 40-48. Go to original source... Go to PubMed...
    15. C.T. Valmadrid, R. Klein, S.E. Moss, et al., The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus, Archives of Internal Medicine 160 (2000) 1093-1100. Go to original source... Go to PubMed...
    16. B.M. Brenner, M.E. Cooper, D. De Zeeuw, et al., Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy, New England Journal of Medicine 345 (2001) 861-869. Go to original source... Go to PubMed...
    17. A.A. Carr, P.R. Kowey, R.B. Devereux, et al., Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies, American Journal of Cardiology 96 (2005) 1530-1536. Go to original source... Go to PubMed...
    18. H.H. Parving, B.M. Brenner, J.J. McMurray, et al., Cardiorenal endpoint in a trial of aliskiren for type 2 diabetes, New England Journal of Medicine 367 (2012) 2204-2213. Go to original source... Go to PubMed...
    19. L.F. Fried, N. Emanuele, J.H. Zhang, et al., Combined angiotensin inhibition for the treatment of diabetic nephropathy, New England Journal of Medicine 369 (2013) 1892-1903. Go to original source... Go to PubMed...
    20. J.F. Mann, D. Green, K. Jamerson, et al., Avosentan for overt diabetic nephropathy, Journal of the American Society of Nephrology 21 (2010) 527-535. Go to original source... Go to PubMed...
    21. B. Zinman, C. Wanner, J.M. Lachin, et al., Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes, New England Journal of Medicine 373 (2015) 2117-2128. Go to original source... Go to PubMed...
    22. C. Wanner, S.E. Inzucchi, J.M. Lachin, et al., Empagliflozin and progression of kidney disease in type 2 diabetes, New England Journal of Medicine 375 (2016) 323-334. Go to original source... Go to PubMed...
    23. B. Neal, V. Perkovic, K.W. Mahaffey, et al., Canagliflozin and cardiovascular and renal events in type 2 diabetes, New England Journal of Medicine 377 (2017) 644-657. Go to original source... Go to PubMed...

    Return to the content


    Cor et Vasa

    You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

    I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.


    No
    Yes